- Aclaris Therapeutics International Limited (ATIL) and Rigel have an exclusive, worldwide license agreement for the development and commercialization of specified Rigel Janus Kinase (JAK) inhibitors, referred to by Aclaris as ATI-502 (topical) and ATI-501 (oral).
- Under the license agreement, ATIL will assume responsibility for the continued development of specified Rigel JAK inhibitor compounds for the treatment of alopecia areata and other dermatological conditions.
- Rigel received an upfront payment of $8 million, and will be eligible to receive various milestone payments of up to $90 million based on global development and multiple indications, as well as tiered royalties on any future sales of these compounds.
- Aclaris has completed enrollment of Phase 2 studies with ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor, and ATI-501, an oral JAK 1/3 inhibitor, both for the potential treatment of alopecia areata. Top line results are expected in Q2 and Q3 of 2019, respectively.
About Alopecia Areata
Alopecia areata is an autoimmune dermatologic condition, typically characterized by patchy, non-scarring hair loss on the scalp and body. The National Alopecia Areata Foundation reports that over 6.6 million Americans have had or will develop alopecia areata at some point in their lives. There is currently no FDA-approved medical treatment for this autoimmune disease. However, it has been reported that systemically administered JAK inhibitors may be potentially efficacious in the treatment of alopecia areata.